By admin 
CureSearch for Children’s Cancer, a national non-profit organization dedicated to ending childhood cancer by driving targeted and innovative research, has formally announced the appointment of John Polson to its Board of Directors. Polson, who serves as the Chairman and Managing Partner of the international labor and employment law firm Fisher Phillips, joins the board at a pivotal juncture for the organization. As CureSearch continues to bridge the gap between academic discovery and clinical application, Polson’s extensive experience in strategic leadership and corporate governance is expected to provide a robust framework for the foundation’s ambitious growth and research-funding objectives.
The appointment marks a significant strengthening of the ties between the legal professional community and the specialized field of pediatric oncology. Polson brings more than three decades of high-level legal expertise and executive management to the CureSearch leadership team. At Fisher Phillips, he oversees the strategic direction, daily operations, and long-term expansion of a firm that maintains 41 offices globally. His tenure has been defined by a focus on operational excellence and a commitment to maintaining the firm’s status as a top-tier legal entity, consistently recognized by prestigious industry barometers such as The Best Lawyers in America and The Legal 500.
A Career Defined by Leadership and Strategic Vision
John Polson’s trajectory within the legal landscape provides a blueprint for the type of executive oversight CureSearch seeks to leverage. Having spent over 30 years navigating the complexities of labor and employment law, Polson has developed a keen understanding of organizational scaling, risk management, and international collaboration. These skills are increasingly vital for non-profit organizations that operate in the highly regulated and globalized environment of medical research and pharmaceutical development.
Under Polson’s stewardship, Fisher Phillips has not only expanded its geographical footprint but has also cultivated a culture of corporate social responsibility. This background is particularly relevant to CureSearch, which relies on a blend of philanthropic support and strategic partnerships with biotechnology firms and academic institutions. Polson’s ability to foster relationships across diverse sectors—ranging from corporate boardrooms to legal forums—positions him as a key asset in CureSearch’s mission to diversify its funding streams and enhance its advocacy efforts.
The Evolution of a Partnership: From Philanthropy to Governance
The transition of John Polson from a dedicated supporter to a board member is the culmination of a multi-year relationship between Fisher Phillips and CureSearch. This partnership has been characterized by tangible results and a shared commitment to the "CureSearch Catapult" model, which focuses on accelerating the pace of drug development for pediatric patients.
A cornerstone of this collaboration has been the firm’s philanthropic arm, FP Cares. Under Polson’s guidance, FP Cares launched a series of initiatives aimed at both financial support and emotional outreach. Most notably, the firm successfully raised $200,000 for CureSearch, providing critical capital for preclinical research projects. Beyond financial contributions, Polson championed the "Notes of Hope" campaign within Fisher Phillips. This initiative saw thousands of firm employees across the globe writing personalized, heartfelt letters to children undergoing intensive cancer treatments, addressing the emotional and psychological toll the disease takes on young patients and their families.
In recognition of these sustained efforts, CureSearch previously honored Fisher Phillips with the "Champion for Cures" award. This accolade is reserved for corporate partners who demonstrate an exceptional level of commitment to the cause, transcending traditional corporate giving to become true stakeholders in the fight against pediatric cancer. Polson’s elevation to the Board of Directors is viewed by industry analysts as a natural progression of this deep-seated commitment.
The Critical Landscape of Pediatric Cancer Research
The timing of Polson’s appointment coincides with a period of significant statistical achievement for CureSearch, yet it also highlights the ongoing challenges within the field of pediatric oncology. While cancer remains the leading cause of death by disease among children in the United States, pediatric research has historically faced a "funding cliff" compared to adult cancer research.
CureSearch has sought to rectify this disparity by focusing on the "Valley of Death"—the precarious stage in medical research where promising laboratory discoveries often fail to reach clinical trials due to a lack of funding or strategic direction. The organization’s current performance metrics are unprecedented in the non-profit sector: approximately 60% of CureSearch-funded preclinical projects are successfully advancing to clinical trials. To put this figure in perspective, the national average for cancer research projects making this transition is a mere 8%.
The disparity between the national average and CureSearch’s success rate underscores the efficacy of their vetting process and their "milestone-based" funding approach. By bringing in a board member with Polson’s background in rigorous professional standards and strategic planning, CureSearch aims to maintain and potentially exceed these metrics. The goal is to ensure that the $4.9 billion spent annually on cancer research in the U.S. includes a more equitable and efficiently managed portion dedicated specifically to the unique biological needs of children.
Official Responses and Stakeholder Perspectives
The leadership at CureSearch has expressed high expectations for the impact Polson will have on the organization’s future. Kay Koehler, President and CEO of CureSearch for Children’s Cancer, emphasized the multifaceted value Polson brings to the table.
"We are thrilled to welcome John Polson to the CureSearch Board of Directors," Koehler stated. "John’s proven leadership, deep commitment to social impact, and ability to build strong relationships will be invaluable as we continue our work to bring life-saving treatments to children with cancer. His experience and vision will help us take our mission to the next level, and we are honored to have him by our side in the fight to end childhood cancer."
For his part, Polson has framed his new role as both a professional responsibility and a personal mission. In his inaugural statement following the appointment, he highlighted the urgency of the cause.
"I am honored to join CureSearch in their fight to end childhood cancer," Polson said. "This is a cause that is very close to my heart, and I look forward to helping drive the organization’s critical work in advancing research and providing hope to children and families affected by cancer."
Chronology of the CureSearch-Polson Alliance
The path to this board appointment reflects a deliberate and impactful timeline of engagement:
- Initial Engagement: Fisher Phillips identifies pediatric cancer as a primary focus for its corporate social responsibility (CSR) initiatives, selecting CureSearch as a key partner due to its data-driven approach.
- Launch of FP Cares: Under Polson’s leadership, the firm formalizes its charitable efforts, creating a structured vehicle for employee giving and firm-wide fundraising.
- The "Notes of Hope" Campaign: The firm mobilizes its global workforce, generating thousands of messages of support for pediatric patients, highlighting the human element of the medical crisis.
- Financial Milestone: Fisher Phillips reaches a cumulative donation total of $200,000, specifically earmarked for high-potential research projects.
- "Champion for Cures" Recognition: CureSearch recognizes the firm’s outsized impact on the pediatric cancer community.
- Board Appointment (Present): John Polson is officially seated on the Board of Directors to provide executive governance and strategic oversight.
Analysis of Implications for Pediatric Oncology
Polson’s appointment is indicative of a broader trend in the non-profit sector where organizations are increasingly seeking "cross-pollination" from the corporate and legal worlds. In the context of pediatric cancer, this is particularly relevant for several reasons:
- Regulatory Navigation: Developing new drugs for children involves complex FDA pathways and international regulatory standards. Polson’s legal background provides a layer of expertise in navigating these administrative hurdles.
- Intellectual Property and Licensing: As CureSearch-funded projects move into clinical trials, issues of intellectual property and licensing with pharmaceutical partners become paramount. A board member with experience in high-stakes corporate law is essential for protecting the interests of the foundation and the patients it serves.
- Scalability of Research: To move from an 8% success rate to a 60% success rate requires more than just scientific brilliance; it requires rigorous project management and accountability. Polson’s experience managing 41 offices worldwide translates directly to overseeing a diverse portfolio of research grants.
- Fundraising Innovation: As traditional donor models evolve, Polson’s connections within the international business community may open doors to new forms of venture philanthropy and corporate partnerships.
Conclusion and Future Outlook
John Polson joins a board comprised of a distinguished group of business leaders, pediatric oncology experts, and patient advocates. This diversity of thought is intentional, aimed at ensuring that CureSearch remains at the forefront of the medical research landscape.
The ultimate objective of this leadership expansion is to transform the prognosis for the thousands of children diagnosed with cancer each year. By integrating high-level corporate strategy with cutting-edge medical science, CureSearch is positioning itself to dismantle the barriers that have historically slowed the development of pediatric-specific treatments.
As Polson begins his tenure, the focus will likely remain on maintaining the momentum of the 60% clinical trial advancement rate. For families affected by childhood cancer, the addition of a strategic heavyweight like Polson to the CureSearch board represents more than just a corporate appointment; it represents a reinforced commitment to finding cures in a timeframe that matters for the children who need them today. The synergy between Polson’s legal acumen and CureSearch’s scientific mission marks a new chapter in the organization’s decades-long effort to ensure that every child diagnosed with cancer has a path to a healthy future.